Evolus Inc

EOLS

Company Profile

  • Business description

    Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

  • Contact

    520 Newport Center Drive
    Suite 1200
    Newport BeachCA92660
    USA

    T: +1 949 284-4555

    E: [email protected]

    https://www.evolus.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    329

Stocks News & Analysis

stocks

Nvidia earnings: Another stellar quarter with no signs of a slowdown

Nvidia remains at the heart of the AI ecosystem.
stocks

Chart of the Week: Software selloff creates opportunity for these two stocks

Can AI disrupt the software business model?
stocks

Market is misinterpreting AI impact on cheap ASX share

Unwarranted sell-off with shares down by half in three months.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,408.7027.40-0.29%
CAC 408,559.0739.860.47%
DAX 4025,175.94189.690.76%
Dow JONES (US)49,482.15307.650.63%
FTSE 10010,806.41125.821.18%
HKSE26,458.56307.16-1.15%
NASDAQ23,152.08288.391.26%
Nikkei 22558,753.39170.270.29%
NZX 50 Index13,670.71145.131.07%
S&P 5006,946.1356.060.81%
S&P/ASX 2009,175.3027.60-0.30%
SSE Composite Index4,146.630.60-0.01%

Market Movers